Bicara Therapeutics Inc. (BCAX) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.
Key numbers for Bicara Therapeutics Inc. (BCAX): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.
AllSight quality score: 38/100 — a percentile rank of Bicara Therapeutics Inc.’s fundamentals against Manufacturing peers, weakest on growth. A quality ranking, not a price prediction.
| Market cap | $1.2B |
| EV / EBITDA | -5.5× |
| Return on equity | -39.5% |
| ROIC | -54.3% |
| Debt / equity | 0.0× |
| Dividend yield | 0.0% |
Independent of the events above — derived from Bicara Therapeutics Inc.’s own financial statements and shown as context, never as advice.
About AllSight · Editorial standards & method · Contact